Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
about
Targeted therapy for localized non-small-cell lung cancer: a reviewNeoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancerLiquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringPlatinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder CancerPhase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).Identification of microRNA-615-3p as a novel tumor suppressor in non-small cell lung cancerAdjuvant or neoadjuvant chemotherapy for NSCLC.Flattened microvessel independently predicts poor prognosis of patients with non-small cell lung cancer.Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis.Pre-operative chemotherapy for non-small cell lung carcinomaExpression of Spindle and Kinetochore-Associated Protein 1 Is Associated with Poor Prognosis in Papillary Thyroid Carcinoma.Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy.MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung CancerYangZheng XiaoJi exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells.Clinical outcomes of surgery after induction treatment in patients with pathologically proven N2-positive stage III non-small cell lung cancer.In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic ModelIs There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the PrognosisAdaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer.A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.Therapeutic management options for stage III non-small cell lung cancer.MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.Current status of induction treatment for N2-Stage III non-small cell lung cancer.Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.Relationship between gene mutation and lung cancer metastasis.Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer.Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.Design, Synthesis and Evaluation of Naphthalimide Derivatives as Potential Anticancer Agents for Hepatocellular Carcinoma.Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.Optimum treatment for mediastinal lymph node positive (N2) resectable non-small cell lung cancer: What is the role for surgery?Chemotherapy remains an essential element of personalized care for persons with lung cancers.TGF-β regulates the proliferation of lung adenocarcinoma cells by inhibiting PIK3R3 expression.Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials.Neoadjuvant combination chemotherapy for unresectable stage III non-small cell lung cancer.The ratio of cancer cells to stroma after induction therapy in the treatment of non-small cell lung cancer.FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells.Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up.
P2860
Q26741441-F77DAAA3-C115-4EDE-B93C-725C46D22A4DQ26863742-3B82C86E-EB59-4030-955F-1A04DF36DEDFQ28076191-845C4F64-88AA-42AC-B3C9-F4A32759795AQ28552143-5FB43439-29C9-4361-8800-DC305925BA14Q33428645-4E2598E1-8552-44A0-B6BE-DE15B0078A91Q33598046-50D0859F-C1FA-4288-965A-DD456B61FA95Q33658228-BA36F474-6E7E-4026-84AA-0812B27D6B45Q33728242-92AB0605-6B79-4815-9179-DAC58CF9E6BDQ34062649-8ED69282-E4F2-4F6E-A08E-B150F5CC2B69Q35200636-0141E828-BAC0-434D-8C39-8BAD29095B6BQ35614372-DD2FD98F-647A-4B3F-A5A4-2089134ECE75Q35681695-95B53215-CE97-49FA-A038-DE600DED6758Q35745088-CB72D1F4-E609-409A-851A-46BDEAB64F06Q35962631-FC08984D-B056-4F6C-9AD2-634E3289679DQ36000921-9713DAAA-30EB-41B4-A1A0-F40B6457E53EQ36138334-ED1A0D96-E14A-4EE7-B440-20E8D42ACFF0Q36140933-D848B1C8-6F3B-4A92-BBCF-BC8EE9E691C9Q36194277-42CD0BDC-8FEA-4EC7-B0C8-97493F86992AQ36195470-D4FE4E06-72D1-4AB9-89CC-7C2247566AC1Q36731328-8E500AF9-1875-43FE-BFCD-B9D4959C3D37Q37478345-F06BBB41-613F-440E-84DF-7391B5A02E04Q37594914-6F7DEDC0-83FC-4518-B18C-3C87CDC3A1FEQ37642455-4DA61136-5A33-4FD6-84BA-869DC12BFA11Q37706182-33546E37-FC8D-4314-A1B9-31C3277879B3Q38263799-9D39C677-33FC-46B5-BA7F-B688B61E029AQ38400481-DDA07C90-E8E9-4D15-BA34-AE2EC16D8571Q38456340-242D16D3-D634-48BC-98F0-DEDFD9849852Q38694837-B0448E83-6834-49B0-9D30-F2B041490370Q38696794-7FE3D71A-4A83-495E-8D1E-9DE8CAC975EDQ38714663-85D4416D-3A99-4341-8F4A-64E18D592889Q38717594-7C8EA1FE-30D4-4AA4-B676-9AAF01136B3FQ38818969-CE3EE7D1-DD19-4765-9174-F0D327820AC0Q38838014-402206D3-BEF8-4BAA-B52E-CDD69083DCF0Q38942628-9496D07A-8EF0-4148-B6A2-081DB9885E9FQ39005340-07773BBD-CA7C-4C9E-A8E2-80494D2C4766Q39034554-F7025857-C7CE-4BEC-9C44-85FB4E5A5508Q40175347-4968A27B-B5EA-4C8D-B405-0E2F35103B13Q40405752-F5A2A326-47EF-4BCD-9F49-27972379A10BQ40918258-49777736-CDC0-405F-9433-40174BE21A1EQ41090595-3B1F8C12-8697-4727-8F81-C3FF5DBAE0BB
P2860
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Preoperative chemotherapy for ...... of individual participant data
@ast
Preoperative chemotherapy for ...... of individual participant data
@en
Preoperative chemotherapy for ...... of individual participant data
@nl
type
label
Preoperative chemotherapy for ...... of individual participant data
@ast
Preoperative chemotherapy for ...... of individual participant data
@en
Preoperative chemotherapy for ...... of individual participant data
@nl
prefLabel
Preoperative chemotherapy for ...... of individual participant data
@ast
Preoperative chemotherapy for ...... of individual participant data
@en
Preoperative chemotherapy for ...... of individual participant data
@nl
P2860
P31
P921
P3181
P1433
P1476
Preoperative chemotherapy for ...... of individual participant data
@en
P2860
P304
P3181
P356
10.1016/S0140-6736(13)62159-5
P407
P577
2014-05-03T00:00:00Z